Angiogenesis Blockade As a New Therapeutic Approach to Experimental Colitis

Overview

Journal Gut

Specialty Gastroenterology

Date 2006 Dec 16

PMID 17170016

Citations 56

Authors

Silvio Danese

Miquel Sans

David M Spencer

Ivy Beck

Fernando Donate

Marian L Plunkett

Carol de la Motte

Raymond Redline

David E Shaw

Alan D Levine

Andrew P Mazar

Claudio Fiocchi

Affiliations

Soon will be listed here.

Abstract

Background: Neoangiogenesis is a critical component of chronic inflammatory disorders. Inhibition of angiogenesis is an effective treatment in animal models of inflammation, but has not been tested in experimental colitis.

Aim: To investigate the effect of ATN-161, an anti-angiogenic compound, on the course of experimental murine colitis.

Method: Interleukin 10-deficient (IL10(-/-)) mice and wild-type mice were kept in ultra-barrier facilities (UBF) or conventional housing, and used for experimental conditions. Dextran sodium sulphate (DSS)-treated mice were used as a model of acute colitis. Mice were treated with ATN-161 or its scrambled peptide ATN-163. Mucosal neoangiogenesis and mean vascular density (MVD) were assessed by CD31 staining. A Disease Activity Index (DAI) was determined, and the severity of colitis was determined by a histological score. Colonic cytokine production was measured by ELISA, and lamina propria mononuclear cell proliferation by thymidine incorporation.

Result: MVD increased in parallel with disease progression in IL10(-/-) mice kept in conventional housing, but not in IL10(-/-) mice kept in UBF. Angiogenesis also occurred in DSS-treated animals. IL10(-/-) mice with established disease treated with ATN-161, but not with ATN-163, showed a significant and progressive decrease in DAI. The histological colitis score was significantly lower in ATN-161-treated mice than in scrambled peptide-treated mice. Inhibition of angiogenesis was confirmed by a significant decrease of MVD in ATN-161-treated mice than in ATN-163-treated mice. No therapeutic effects were observed in the DSS model of colitis. ATN-161 showed no direct immunomodulatory activity in vitro.

Conclusion: Active angiogenesis occurs in the gut of IL10(-/-) and DSS-treated colitic mice and parallels disease progression. ATN-161 effectively decreases angiogenesis as well as clinical severity and histological inflammation in IL10(-/-) mice but not in the DDS model of inflammatory bowel disease (IBD). The results provide the rational basis for considering anti-angiogenic strategies in the treatment of IBD in humans.

Citing Articles

In Vivo Assessment of Deep Vascular Patterns in Murine Colitis Using Optoacoustic Mesoscopic Imaging.

Buehler A, Brown E, Nedoschill E, Eckstein M, Ludwig P, Wachter F Adv Sci (Weinh). 2024; 11(45):e2404618.

PMID: 39439243 PMC: 11615813. DOI: 10.1002/advs.202404618.

Mechanoelectronic stimulation of autologous extracellular vesicle biosynthesis implant for gut microbiota modulation.

Wan S, Wang K, Huang P, Guo X, Liu W, Li Y Nat Commun. 2024; 15(1):3343.

PMID: 38637580 PMC: 11026491. DOI: 10.1038/s41467-024-47710-w.

Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis.

Bernardi F, DAmico F, Bencardino S, Faggiani I, Fanizza J, Zilli A Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543132 PMC: 10975629. DOI: 10.3390/ph17030347.

Gut-liver axis calibrates intestinal stem cell fitness.

Kim G, Chen Z, Li J, Luo J, Castro-Martinez F, Wisniewski J Cell. 2024; 187(4):914-930.e20.

PMID: 38280375 PMC: 10923069. DOI: 10.1016/j.cell.2024.01.001.

Pathological mechanism and targeted drugs of ulcerative colitis: A review.

Guo M, Wang X Medicine (Baltimore). 2023; 102(37):e35020.

PMID: 37713856 PMC: 10508406. DOI: 10.1097/MD.0000000000035020.

References

Gould V, Wagner B . Angiogenesis: an expanding universe. Hum Pathol. 2002; 33(11):1061-3. DOI: 10.1053/hupa.2002.130311. View

Kumar C . Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003; 4(2):123-31. DOI: 10.2174/1389450033346830. View

Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry G, Parikh A . Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003; 104(4):496-503. DOI: 10.1002/ijc.10958. View

Libby P, Zhao D . Allograft arteriosclerosis and immune-driven angiogenesis. Circulation. 2003; 107(9):1237-9. DOI: 10.1161/01.cir.0000059744.64373.08. View

Moulton K, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E . Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003; 100(8):4736-41. PMC: 153625. DOI: 10.1073/pnas.0730843100. View

Carmeliet P . Angiogenesis in health and disease. Nat Med. 2003; 9(6):653-60. DOI: 10.1038/nm0603-653. View

McDonald D, Choyke P . Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003; 9(6):713-25. DOI: 10.1038/nm0603-713. View

Kim S, Harris M, Varner J . Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem. 2000; 275(43):33920-8. DOI: 10.1074/jbc.M003668200. View

Walsh D, Pearson C . Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res. 2001; 3(3):147-53. PMC: 128891. DOI: 10.1186/ar292. View

10.

Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T . Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol. 2001; 168(1):450-7. DOI: 10.4049/jimmunol.168.1.450. View

11.

Spencer D, Veldman G, Banerjee S, Willis J, Levine A . Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology. 2002; 122(1):94-105. DOI: 10.1053/gast.2002.30308. View

12.

Klein S, de Fougerolles A, Blaikie P, Khan L, Pepe A, Green C . Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol. 2002; 22(16):5912-22. PMC: 133962. DOI: 10.1128/MCB.22.16.5912-5922.2002. View

13.

Wilder R . Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis. 2002; 61 Suppl 2:ii96-9. PMC: 1766704. DOI: 10.1136/ard.61.suppl_2.ii96. View

14.

McLaren W, Anikijenko P, Thomas S, Delaney P, King R . In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci. 2002; 47(11):2424-33. DOI: 10.1023/a:1020631220599. View

15.

Storgard C, Stupack D, Jonczyk A, Goodman S, Fox R, Cheresh D . Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999; 103(1):47-54. PMC: 407856. DOI: 10.1172/JCI3756. View

16.

Moulton K, Heller E, Konerding M, Flynn E, Palinski W, Folkman J . Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999; 99(13):1726-32. DOI: 10.1161/01.cir.99.13.1726. View

17.

Eliceiri B, Cheresh D . The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999; 103(9):1227-30. PMC: 408360. DOI: 10.1172/JCI6869. View

18.

Xia Y, Li B, Hylton D, Detmar M, Yancopoulos G, Rudge J . Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003; 102(1):161-8. DOI: 10.1182/blood-2002-12-3793. View

19.

Dredge K, Dalgleish A, Marriott J . Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs. 2003; 4(6):667-74. View

20.

Liu E, Ye Y, Shin V, Yuen S, Leung S, Wong B . Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis. 2003; 24(8):1407-13. DOI: 10.1093/carcin/bgg094. View